Robert W. Selander
Known title: DirectorCIK: 0001160228
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Equifax Preps Q3 Earnings and Expands Cash Flow Data Tools. Equifax is preparing to report its third-quarter earnings, a key upcoming event for the stock. Additionally, the company announced an expansion of its cash flow data solutions to help lenders make more confident decisions. These developments occur while the stock trades near its upper 52-week range, with analysts maintaining a wide target price spread.
Transaction History
| HQY | ▲ Buy | Grant | 2,877 | $0 | 6/25/2026 | View on chart |
| HQY | ▲ Buy | Grant | 2,003 | $0 | 6/26/2025 | View on chart |
| HQY | ▲ Buy | Option Exercise | 12,500 | $359K | 4/9/2025 | View on chart |
| HQY | ▼ Sell | Open Market | 2,067 | $159K | 4/9/2025 | View on chart |
| HQY | ▼ Sell | Open Market | 3,283 | $256K | 4/9/2025 | View on chart |
| HQY | ▼ Sell | Open Market | 400 | $32K | 4/9/2025 | View on chart |
| HQY | ▲ Buy | Option Exercise | 12,500 | $359K | 2/10/2025 | View on chart |
| HQY | ▼ Sell | Open Market | 3,752 | $416K | 2/10/2025 | View on chart |
| HQY | ▼ Sell | Open Market | 1,998 | $224K | 2/10/2025 | View on chart |
| HQY | ▼ Sell | Open Market | 5,750 | $584K | 12/9/2024 | View on chart |
| HQY | ▲ Buy | Option Exercise | 7,500 | $160K | 12/9/2024 | View on chart |
| HQY | ▼ Sell | Open Market | 2,500 | $254K | 12/9/2024 | View on chart |
| HQY | ▲ Buy | Option Exercise | 12,500 | $359K | 12/9/2024 | View on chart |
| HQY | ▲ Buy | Option Exercise | 12,500 | $359K | 10/9/2024 | View on chart |
| HQY | ▼ Sell | Open Market | 1,504 | $123K | 10/9/2024 | View on chart |
| HQY | ▼ Sell | Open Market | 4,171 | $347K | 10/9/2024 | View on chart |
| HQY | ▼ Sell | Open Market | 75 | $6K | 10/9/2024 | View on chart |
| HQY | ▲ Buy | Option Exercise | 7,500 | $160K | 10/9/2024 | View on chart |
| HQY | ▼ Sell | Open Market | 752 | $62K | 10/9/2024 | View on chart |
| HQY | ▼ Sell | Open Market | 1,748 | $146K | 10/9/2024 | View on chart |
| HQY | ▲ Buy | Grant | 2,543 | $0 | 7/5/2024 | View on chart |
| HQY | ▲ Buy | Grant | 3,164 | $0 | 6/22/2023 | View on chart |
| HQY | ▲ Buy | Grant | 2,996 | $0 | 6/23/2022 | View on chart |
| EFX | ▲ Buy | Grant | 865 | $0 | 5/5/2022 | View on chart |
| HQY | ▲ Buy | Grant | 727 | $0 | 2/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
HealthEquity Appoints Moody's CFO to Board Amid AI Cash Concerns
HealthEquity has appointed Noémie Heuland, CFO of Moody's, to its board of directors. This governance move comes as market commentary highlights concerns regarding the company's cash position in the context of AI adoption. The stock is currently trading near its 52-week low, with an average analyst target price of $119.33.
HealthEquity Appoints Moody's CFO to Board Amid AI Cash Concerns. HealthEquity has appointed Noémie Heuland, CFO of Moody's, to its board of directors. This governance move comes as market commentary highlights concerns regarding the company's cash position in the context of AI adoption. The stock is currently trading near its 52-week low, with an average analyst target price of $119.33.